Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.77 |
| ▸ | MAOB | P27338 | 1/20 | 0.72 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.69 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | F2 | P00734 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27603151 | 0.98 | NR4A2 (0.74) | NR4A2MAOBPARP10SMPD1SRD5A2 | |
| SCHEMBL19980221 | 0.90 | F10 (0.72) | NR4A2MAOBPARP10PTPN1F2 | |
| SCHEMBL7451063 | 0.89 | NR4A2 (0.70) | NR4A2MAOBPARP10SMPD1SRD5A2 | |
| SCHEMBL7444275 | 0.88 | NR4A2 (0.60) | NR4A2MAOBPARP10SMPD1SRD5A2 | |
| SCHEMBL7442228 | 0.88 | F2 (0.63) | NR4A2MAOBPARP10SMPD1F2 | |
| SCHEMBL202497 | 0.88 | F2 (0.61) | NR4A2MAOBPARP10F2 | |
| SCHEMBL30207018 | 0.87 | NR4A2 (1.00) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL2666406 | 0.87 | MEN1 (0.75) | NR4A2MAOBPARP10SMPD1SRD5A2 | |
| SCHEMBL339009 | 0.87 | NR4A2 (1.00) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL7908051 | 0.87 | SRD5A2 (0.85) | NR4A2MAOBSMPD1SRD5A2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037412-B1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2020-09-30 | — | — | EP | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-9868731-B2 | Indole amide compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2018-01-16 | — | — | US | claimed |
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-07 | — | — | US | claimed |
| EP-3037412-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | claimed |
| CN-1081624-C | Benzamide analogs, useful as PARP (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors | NEWCASTLE UNIV VENTURE INVEST (GB) | 2002-03-27 | — | — | CN | claimed |
| EP-0749415-B1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | UNIV NEWCASTLE VENTURES LTD (GB) | 1999-09-08 | — | — | EP | claimed |
| US-5756510-A | POTENTIATE EFFECTS OF CYTOTOXIC DRUGS OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-26 | — | — | US | claimed |
| JP-H09510704-A | — | — | 1997-10-28 | — | — | JP | claimed |
| CN-1143358-A | Benzamide analogs, useful as parp (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors | UNIV NEWCASTLE VENTURES LTD (GB) | 1997-02-19 | — | — | CN | claimed |
| EP-0749415-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1996-12-27 | — | — | EP | claimed |
| WO-1995024379-A1 | BENZAMIDE ANALOGS, USEFUL AS PARP (ADP-RIBOSYLTRANSFERASE, ADPRT) DNA REPAIR ENZYME INHIBITORS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1995-09-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194313-A1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | NR4A2 2730/4885MAOB 162/4885PARP10 2576/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | NR4A2 1841/4885MAOB 1020/4885PARP10 4650/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | NR4A2 1528/4885MAOB 1634/4885PARP10 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.